Noninfectious transfusion of platelets donated before detection of human immunodeficiency virus RNA in plasma

Transfusion

Volumn 49, Issue 3, 2009, Pages 435-439

  Kalus, Ulrich ^a   Edelmann, Anke ^a   Pruss, Axel ^a   Hofmann, Jörg ^a   Kiesewetter, Holger ^a   Krüger, Detlev H ^a   Salama, Abdulgabar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADULT; ANTIBODY SCREENING; ANTIGEN ANTIBODY COMPLEX; APHERESIS; ARTICLE; BLOOD DONOR; CASE REPORT; DISEASE MARKER; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PLASMA; SCREENING TEST; THROMBOCYTE TRANSFUSION; VIRUS DETECTION;

ADULT; BLOOD DONORS; HIV INFECTIONS; HUMANS; MALE; PLATELET TRANSFUSION; RNA, VIRAL;

EID: 60149086791     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.02012.x     Document Type: Article

References (28)

1. Busch MP, Kleinman SH. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases. Transfusion 2000 40 143 59.
2. Aprili G, Gandini G, Piccoli P, Bressan F, De Gironcoli M, Mazzi R, Parisi SG, Gessoni G, Marchiori G, Franchini M. Detection of an early HIV-1 infection by HIV RNA testing in an Italian blood donor during the preseroconversion window period. Transfusion 2003 43 848 52.
3. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 254 6.
4. Dodd RY, Notari IV, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 975 9.
5. Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007 131 702 7.
6. O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007 47 316 25.
7. Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, Hedges D, Seifried E. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002 42 862 8.
8. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008 48 1558 66.
9. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351 760 8.
10. Busch MP, Dodd RY. NAT and blood safety: what is the paradigm? Transfusion 2000 40 1157 60.
11. Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SY, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, Chamberland ME, Busch MP, Folks TM, Kalish ML. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000 284 210 4.
12. Delwart EL, Kalmin ND, Jones TS, Ladd DJ, Foley B, Tobler LH, Tsui RC, Busch MP. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 2004 86 171 7.
13. Phelps R, Robbins K, Liberti T, Machuca A, Leparc G, Chamberland M, Kalish M, Hewlett I, Folks T, Lee LM, McKenna M. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004 44 929 33.
14. Schmidt M, Korn K, Nuebling M, Chudy M, Geusendam G, Hennig H, Sireis W, Rabenau HF, Doerr HW, Berger A, Hourfar MK, Gubbe K, Karl A, Guertler L, Seifried E. First transmission of HIV-1 by a cellular blood product after mandatory NAT blood screening in Germany. Vox Sang 2008 95 s1 56.
15. Kopko PM, Fernando LP, Bonney EN, Freeman JL, Holland PV. HIV transmissions from a window-period platelet donation. Am J Clin Pathol 2001 116 562 6.
16. Zanetti AR, Bodini U, Clerici M, Romanò L, Paolini E, Biasin M, Amendola A, Velati C. Transfusion of red blood cells from an HIV-RNA-positive/anti-HIV-negative donor without HIV infection in the recipient. Transfusion 2007 47 1328 9.
17. Ferreira MC, Nel TJ. Differential transmission of human immunodeficiency virus (HIV) via blood components from an HIV-infected donor. Transfusion 2006 46 156 7.
18. Drosten C, Seifried E, Roth WK. TaqMan 5′-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening. Clin Microbiol 2001 39 4302 8.
19. Coombs RW, Collier AC, Allain JP, Nikora B, Leuther M, Gjerset GF, Corey L. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989 321 1626 31.
20. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, Shaw GM. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991 324 954 60.
21. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991 324 961 4.
22. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G. NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 1991 114 678 93.
23. Piatak M Jr., Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993 259 1749 54.
24. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997 102 117 24 discussion KK, Henrard DR, Eichberg JW, Cobb KE, Busch MP, Allain JP, Alter HJ. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999 39 688 93.
25. Grand RL, Nadal M, Cheret A, Roques P, Vaslin B, Matheux F, Theodoro F, Gras G, Gauthier L, Aubertin AM, Dormont D. Infection of macaques after vaginal exposure to a primary isolate of SIV mac251. AIDS 1995 9 308 9.
26. Ma ZM, Abel K, Rourke T, Wang Y, Miller CJ. A period of transient viremia and occult infection precedes persistent viremia and antiviral immune responses during multiple low-dose intravaginal simian immunodeficiency virus inoculations. J Virol 2004 78 14048 52.
27. Amedee AM, Rychert J, Lacour N, Fresh L, Ratterree M. Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques. Retrovirology 2004 1 17.
28. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003 17 1871 9.